Markus Staudt

Dr. Markus Staudt


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MSMarkus Staudt
Markus Staudt
MHMatthias M. Herth
Matthias M. Herth
‘Pretargeting’ led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

1 February 2021
Verified
Book Chapter
Open access
PDF file
MSMarkus Staudt
Markus Staudt
MHMatthias M. Herth
Matthias M. Herth
CPChristian Poulie
Christian Poulie
Personalized medicine is becoming an integral part of our healthcare system, in which theranostics play a fundamental role. Nanomedicines such as monoclonal antibodies are a commonly used targeting vector in such approaches due to their outstanding targeting abilities as well as their capabilities to function as drug delivery vehicles. However, the application of nanomedicines in a clinical setting is connected with several challenges. For example, nanomedicines typically possess slow pharmacokinetics in respect to target accumulation and excretion. For targeted radionuclide therapy, this results in high radiation burden to healthy tissue. For drug delivery systems, long circulation and excretion times of the nanomedicine complicate site-specific release approaches and limit as such the usability of these strategies. One way to circumvent these challenges is the use of pretargeting strategies, which allow to separate the accumulation and excretion of nanomedicines from the actual diagnostic or therapeutic application. As such, pretargeting allows to use theranostic concepts utilizing the same nanomedicine and determine the success chances with diagnostic measures before initiating therapy. This chapter will explain the concept of pretargeted theranostics, which pretargeting systems have thus far been developed and compare how these systems performed.

28 November 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
MMMarius Müller
Marius Müller
VSVladimir Shalgunov
Vladimir Shalgunov
LHLars Hvass
Lars Hvass
JJJesper T. Jørgensen
Jesper T. Jørgensen
VKVasko Kramer
Vasko Kramer
MHMatthias M. Herth
Matthias M. Herth

13 March 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
LHLars Hvass
Lars Hvass
MMMarius Müller
Marius Müller
MSMarkus Staudt
Markus Staudt
RGRocio García-Vázquez
Rocio García-Vázquez
TGTobias K. Gustavsson
Tobias K. Gustavsson
Andreas KjaerAndreas Kjaer
Andreas Kjaer
Pretargeted imaging harnessing tetrazine ligation has gained increased interest over recent years. Targeting vectors with slow pharmacokinetics may be visualized using short-lived radionuclides, such as fluorine-18 (18F) for positron emission tomography (PET), and result in improved target-to-background ratios compared to conventionally radiolabeled slowly accumulating vectors. We recently developed different radiochemical protocols enabling the direct radiofluorination of various tetrazine scaffolds, resulting in the development of various highly reactive and polar 18F-labeled tetrazines as lead candidates for pretargeted imaging. Here, we performed a direct head-to-head-comparison of our lead candidates to evaluate the most promising for future clinical translation. For that, all 18F-labeled tetrazine-scaffolds were synthesized in similar molar activity for improved comparability of their in vivo pretargeting performance. Intriguingly, previously reported dicarboxylic acid lead candidates with a net charge of -1 were outperformed by respective monocarboxylic acid derivatives bearing a net charge of 0, warranting further evaluation of such scaffolds prior to their clinical translation.

17 June 2025 in ACS Central Science
Verified
Journal Article
Open access
MSMarkus Staudt
Markus Staudt
JCJonathan C. T. Carlson
Jonathan C. T. Carlson
Screening the tetrazine-protein interactome finds the balance needed for high-performance fluorescent probes.

30 September 2024 in ACS Omega
Verified
Journal Article
Open access
MSMarkus Staudt
Markus Staudt
LHLars Hvass
Lars Hvass
MMMarius Müller
Marius Müller
RGRocío García-Vázquez
Rocío García-Vázquez
JJJesper Tranekjær Jo̷rGensen
Jesper Tranekjær Jo̷rGensen
MHMatthias M. Herth
Matthias M. Herth
Polar BODIPY-tetrazine dyes were developed and clicked in vivo to a preaccumulated trans-cyclooctene-modified anti-TAG72 monoclonal antibody CC49 (CC49-TCO). The in vivo click performance was evaluated using an in-house developed ex vivo blocking assay. All tested polar BODIPY structures exhibited excellent in vivo binding, confirming that the turn-on tetrazine dyes successfully clicked in vivo to pretargeted CC49-TCO. Fluorescence imaging showed high tumor-to-muscle ratios of 4:1. This proof-of-concept study indicates that the pretargeting concept based on turn-on probes could be used for cancer treatments, such as photodynamic or -thermal therapy.